The release of early-stage data on three oral weight loss drug candidates hints at which companies have the strongest hand, ...

The weight-loss market is heating up as a number of companies are looking for a way to upend the dominance of market leaders Novo Nordisk ( NVO) and Eli Lilly ( LLY) by introducing GLP-1 pills.

Roche presented early-stage data on its obesity injection and pill at EASD. Meanwhile, Oura enters into metabolic health market with acquisition of Veri.

Jared Holz thought about taking one of the new GLP-1 drugs for weight loss for months before he actually filled the prescription. And even when he got the drug, he waited a month before using it.

Reuters.com is your online source for the latest news stories and current events, ensuring our readers up to date with any breaking news developments ...

Roughly three-quarters of people who took both an injectable and pill version of a new GLP-1 weight loss drug in trials ...

A lint roller or tape is sometimes strong enough to remove light pilling from clothes made of cotton or wool, but the most ...

This health news summary discusses the mpox vaccine stockpiles in rich nations, Moderna's financial forecast, Morocco's first ...

Recently revealed trial results for Roche's experimental weight-management drug suggest Viking Therapeutics is on the right ...

The Switzerland-based pharmaceutical company has been trying to crack the weight-loss boom currently dominated by Eli Lilly ...

Rise and shine, everyone, another busy day is on the way. However, this is also shaping up as a beautiful day as well, despite forecasts predicting rising ...

When doses werer increased rapidly in a Phase I study, patients on Roche’s investigational oral GLP-1 receptor agonist experienced nausea, vomiting, constipation, diarrhea, as well as abdominal and ...